These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9592806)

  • 41. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
    Neuvonen PJ; Kantola T; Kivistö KT
    Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine.
    Isohanni MH; Neuvonen PJ; Palkama VJ; Olkkola KT
    Eur J Clin Pharmacol; 1998 Sep; 54(7):561-5. PubMed ID: 9832299
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine.
    Isohanni MH; Neuvonen PJ; Olkkola KT
    Pharmacol Toxicol; 1999 Mar; 84(3):143-6. PubMed ID: 10193676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
    Antila S; Honkanen T; Lehtonen L; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Results of a clinical trial with bromperidol C-C 2489/21.
    Weiser G
    Acta Psychiatr Belg; 1978; 78(1):102-9. PubMed ID: 347873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients.
    Brannen JO; McEvoy JP; Wilson WH; Petrie WM; Ban TA; Berney SA; Schaffer JD
    Pharmacopsychiatria; 1981 Jul; 14(4):139-40. PubMed ID: 6116246
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacokinetics of haloperidol: an update.
    Kudo S; Ishizaki T
    Clin Pharmacokinet; 1999 Dec; 37(6):435-56. PubMed ID: 10628896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof.
    Suzuki H; Gen K; Inoue Y
    J Psychopharmacol; 2013 Apr; 27(4):396-400. PubMed ID: 23427194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bromperidol maintenance in schizophrenia.
    McEvoy JP; Wilson WH; Ban TA; Brannen JO; Berney S
    Pharmacopsychiatria; 1982 May; 15(3):95-6. PubMed ID: 7100263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.
    Šimić I; Potočnjak I; Kraljičković I; Stanić Benić M; Čegec I; Juričić Nahal D; Ganoci L; Božina N
    Pharmacogenomics; 2016 Aug; 17(13):1385-9. PubMed ID: 27469576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Possible interaction between cisapride and bromperidol.
    Ishida M; Otani K; Yasui N; Inoue Y; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 Jan; 21(1):235-8. PubMed ID: 9075269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
    Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
    Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
    van der Weide K; van der Weide J
    J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
    Maxa JL; Melton LB; Ogu CC; Sills MN; Limanni A
    Ann Pharmacother; 2002 May; 36(5):820-3. PubMed ID: 11978159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography.
    Yasui-Furukori N; Inoue Y; Chiba M; Tateishi T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(1):175-80. PubMed ID: 15113555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Double-blind comparison of bromperidol and perphenazine.
    Woggon B; Angst J
    Int Pharmacopsychiatry; 1978; 13(3):165-76. PubMed ID: 355182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.